GCP
HOWL icon

GSA Capital Partners’s Werewolf Therapeutics HOWL Stock Holding History

GSA Capital Partners’s Portfolio HOWL Stock Details HOWL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10K Buy
+27,146
New +$16.5K ﹤0.01% 1690

Other funds holding HOWL

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
DF
DC Funds Mclean, Virginia $1.25M AUM 26.51% 1-Year Est. Return
VA
Verdad Advisers Boston, Massachusetts $104M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

GSA Capital Partners's HOWL Position: Q2 2026 in Review

GSA Capital Partners opened a new position in Werewolf Therapeutics (HOWL) in Q2 2026: 27,146 shares worth $10K. The stake represents ﹤0.01% of the portfolio and ranks #1690 among its holdings.

42 funds tracked by Wall St. Rank hold HOWL as of Q2 2026.

  • GSA Capital Partners held 27,146 shares of Werewolf Therapeutics worth $10K as of Q2 2026.
  • Werewolf Therapeutics was a new GSA Capital Partners position in Q2 2026.
  • Werewolf Therapeutics made up ﹤0.01% of GSA Capital Partners's portfolio in Q2 2026, its #1690 holding.
  • 42 funds tracked by Wall St. Rank held Werewolf Therapeutics as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.